Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 9/20 | 0.34 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.32 |
| ▸ | PGR | P06401 | 3/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561562 | 0.84 | PLA2G2A (0.37) | SRD5A1PLA2G2AXDHMEN1MAPT | |
| SCHEMBL6561182 | 0.77 | ALDH1A1 (0.47) | PLA2G2AXDHMEN1KMT2AALDH1A1 | |
| SCHEMBL6398012 | 0.69 | SRD5A1 (0.49) | SRD5A1XDHMEN1MAPTKMT2A | |
| SCHEMBL6561697 | 0.69 | BIRC5 (0.38) | SRD5A1PLA2G2AXDHMEN1MAPT | |
| SCHEMBL7856928 | 0.68 | SRD5A1 (0.40) | SRD5A1PLA2G2AMEN1MAPTKMT2A | |
| SCHEMBL323547 | 0.67 | XDH (0.54) | SRD5A1XDHMEN1MAPTKMT2A | |
| SCHEMBL5975117 | 0.66 | NR3C1 (0.41) | GRM2NR3C1PGRNR3C2HTR2C | |
| SCHEMBL7853922 | 0.66 | SRD5A1 (0.36) | SRD5A1PLA2G2AMEN1MAPTKMT2A | |
| SCHEMBL4370066 | 0.65 | SRD5A1 (0.42) | SRD5A1PLA2G2AXDHMEN1MAPT | |
| Hydrogen Sulfide SCHEMBL6721312 | 0.65 | XDH (0.52) | SRD5A1XDHMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960417-B2 | Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders | MERCK SHARP & DOHME CORP. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | MERCK SHARP & DOHME CORP. | 2008-07-24 | — | — | US | disclosed |
| EP-1855670-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006091496-A2 | BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-0948327-B1 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-0948327-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6515015-B1 | In combination with one or more known sulfonylureas, biguanides, alpha -glucosidase inhibitors, other insulin secretogogues or insulin | MERCK & CO. INC. | 2003-02-04 | — | — | US | disclosed |
| US-6160000-A | Antidiabetic agents based on aryl and heteroarylacetic acids | MERCK & CO., INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6090839-A | REDUCING TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0948327-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998027974-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176904-A1 | Benzazole Potentiators of Metabotropic Glutatmate Receptors | GRM2, GRM3, GRIK2 | SRD5A1 3536/4885GRM2 1/4885PLA2G2A 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.